[Interferon and plasma lipids].
García-Escaño
M D
MD
Departamento de Medicina, Facultad de Medicina, Málaga.
Andrade
R J
RJ
González-Santos
P
P
D000208:Acute Disease; D000437:Alcoholism / Q000150:complications; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001059:Apoproteins / Q000097:blood; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D048909:Diabetes Complications; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D007372:Interferons / Q000009:adverse effects* / Q000627:therapeutic use*; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D010195:Pancreatitis / Q000139:chemically induced; D012307:Risk Factors; D014280:Triglycerides / Q000096:biosynthesis / Q000097:blood
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001059:Apoproteins; D008076:Cholesterol, HDL; D016898:Interferon-alpha; D008055:Lipids; D008077:Lipoproteins, LDL; D014280:Triglycerides; D016899:Interferon-beta; D007372:Interferons; D002784:Cholesterol